Abstract
Early-stage mycosis fungoides (stage IA–IIA) may be treated with skin-directed therapy (topical corticosteroids, topical mechlorethamine, superficial radiotherapy and phototherapy). Advanced or refractory disease may require systemic therapy, such as chemotherapy, extracorporeal photopheresis (ECP) or immunotherapy. Although chemotherapy produces a good response in cutaneous T-cell lymphoma (CTCL), it is frequently short lived. Morbidity is common with chemotherapy and infection or septicemia may be preterminal. There has been a burst of novel therapies for the treatment of advanced and refractory CTCL over the past decade, including retinoid X receptor-selective retinoids, monoclonal antibodies, immunotherapy and histone deacetylase inhibitors. Most of these therapeutic agents are still being developed and are being used in Phase I–III clinical trials. However, bexarotene, a retinoid X receptor-selective retinoid, was approved for the treatment of CTCL in 1999 and has efficacy in both early and advanced ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
